About: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial
Creator	Mouthon, Luc Morbieu, Caroline Audureau, Etienne Carlier, Nicolas Lescure, Xavier Ravaud, Philippe Roche, Nicolas Schlemmer, Frédéric Szwebel, Tali-Anne Terrier, Benjamin Tran, Viet-Thi Crickx, Etienne Dang, Julien Godeau, Bertrand Legendre, Paul Mahévas, Matthieu Michel, Marc Chabrol, Amélie Costedoat-Chalumeau, Nathalie Gallien, Sébastien Guillaud, Constance Lepeule, Raphael Paule, Romain Perrodeau, Elodie Roumier, Mathilde Schoindre, Yoland De Lastours, Victoire Khellaf, Medhi Matignon9, Marie Pawlotski, Jean-Michel
Source	MedRxiv
abstract	Background Treatments are urgently needed to prevent respiratory failure and deaths from coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide attention because of positive results from small studies. Methods We used data collected from routine care of all adults in 4 French hospitals with documented SARS-CoV-2 pneumonia and requiring oxygen ≥ 2 L/min to emulate a target trial aimed at assessing the effectiveness of HCQ at 600 mg/day. The composite primary endpoint was transfer to intensive care unit (ICU) within 7 days from inclusion and/or death from any cause. Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results This study included 181 patients with SARS-CoV-2 pneumonia; 84 received HCQ within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group). Initial severity was well balanced between the groups. In the weighted analysis, 20.2% patients in the HCQ group were transferred to the ICU or died within 7 days vs 22.1% in the no-HCQ group (16 vs 21 events, relative risk [RR] 0.91, 95% CI 0.47-1.80). In the HCQ group, 2.8% of the patients died within 7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13-2.89), and 27.4% and 24.1%, respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI 0.65-2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring HCQ discontinuation. Interpretation These results do not support the use of HCQ in patients hospitalised for documented SARS-CoV-2-positive hypoxic pneumonia.
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.1101/2020.04.10.20060699
has license	medrxiv
sha1sum (hex)	f9cf27a10df8349bb5787688c6c82bbc598c3bc0
schema:url	https://doi.org/10.1101/2020.04.10.20060699
resource representing a document's title	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial
resource representing a document's body	covid:f9cf27a10df8349bb5787688c6c82bbc598c3bc0#body_text
is schema:about of	named entity 'prevent' named entity 'attention' named entity 'TO PREVENT' named entity 'DATA' named entity 'needed' named entity 'collected' named entity 'evidence' named entity 'HCQ' named entity 'oxygen' named entity 'COVID' named entity 'medRxiv' named entity 'protein' named entity 'SARS-CoV-2' named entity 'electrocardiogram' named entity 'follow-up' named entity 'preprint' named entity 'HCQ' named entity 'viral infection' named entity 'ARDS' named entity 'respiratory failure' named entity 'randomly assigned' named entity 'COVID' named entity 'HCQ' named entity 'control group' named entity 'intensive care unit' named entity 'preprint' named entity 'pneumonia' named entity 'first-degree atrioventricular block' named entity 'asthma' named entity 'pneumonia' named entity 'SLE' named entity 'medRxiv' named entity 'ritonavir' named entity 'HCQ' named entity 'positive airway pressure' named entity 'systemic lupus erythematous' named entity 'tertiary care centres' named entity 'COVID-19' named entity 'endosomal' named entity 'corrected QT interval' named entity 'pathology' named entity 'HCQ' named entity 'cytokine storm' named entity 'virus shedding' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'COVID' named entity 'prognosis' named entity 'contraindication' named entity 'medRxiv' named entity 'pneumonia' named entity 'peer-reviewed' named entity 'CC-BY-NC-ND 4.0' named entity 'ARDS' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software